GIC invests HK$659m in Bloomage in bet on Botox
Singapore
GIC Pte's private-equity unit has invested HK$659 million (S$119 million) in Hong-Kong listed Bloomage BioTechnology Corporation Ltd, as it taps into China's growing medical cosmetics market.
The investment consists of HK$465 million convertible bonds and HK$194 million new shares at a subscription price of HK$12 each, Singapore's GIC and Bloomage said in a joint statement on Thursday. Bloomage shares surged 8.2 per cent to HK$15 in Hong Kong at 2:55pm.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Meituan to debut in Riyadh as expansion beyond China quickens
Mapletree Industrial Trust to distribute S$13 million of divestment gains over next 4 quarters
K-pop agency Hybe’s internal strife wipes out 1.2 trillion won
Beijing city to subsidise domestic AI chips, targets self-reliance by 2027
Hong Kong bourse regains favour on hopes of a market revival
Chinese sellers go to TikTok school to reach buyers abroad